CD4+ T-cell Count Useful to Assess Antiretroviral Therapy Response in HTLV-1/HIV Patients
The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients were more likely to have higher CD4+ T-cell counts prior to treatment initiation with no immunologic benefit--a result that has been well documented in scholarly literature. Any differences in the CD4+ T-cell counts were expected to disappear once the co-infected and mono-infected patients began to fail their antiretroviral therapy (ART) regimens.Instead, the authors found that HTLV-1/HIVco-infected patients continued to have elevated CD4+ T-cell counts, on average 115 cells/μL higher than their HIV mono-infected counterparts, over the two-year study period. But when the authors compared the HIV viral loads over the same period, they could not find any statistically significant difference between the two groups of patients. HIV viral load testing is currently recommended by the World Health Organization (WHO) as an accurate strategy for monitoring a patient's response to ART. Nevertheless, CD4+ T-cell testing is often used in resource-limited settings because it is perceived to be more affordable. The continued use of CD4+ T-cell testing has implications for the clinical management of HIV-positive patients. Results from the present study suggest that HTLV-1/HIV co-infection could delay the identification of patients who are failing ART with adverse consequences.Against this background, recent scientific research has begun to show that HIV viral load testing can be both an accurate and cost-effective treatment monitoring strategy. The present study was based in the KwaZulu-Natal province of South Africa and used patient data from a poor and rural community at the epicenter of the global HIV epidemic.Source: Bentham Science Publishers
Pseudomonas aeruginosa: Infection Risks, Challenges, and Breakthroughs for Health Care Professionals
September 19th 2024Pseudomonas aeruginosa, a highly virulent pathogen, poses significant risks to immunocompromised patients, presenting challenges in treatment due to its antibiotic resistance and environmental persistence.
Advancing Infection Prevention With Diagnostic Innovation: Insights From Alesia McKeown, PhD
September 17th 2024Alesia McKeown, PhD, discusses the pivotal role of cutting-edge diagnostic technologies in enhancing infection prevention, especially in high-risk health care environments, during an interview with Infection Control Today.
The Role of Accurate Testing in Preventing Respiratory Illnesses: Insights from Dr. Aparna Ahuja
September 17th 2024On Get Ready for Flu Day, Dr. Aparna Ahuja discusses the importance of accurate respiratory illness testing, the risks of self-diagnosis, and the role of infection prevention personnel in public health education.
How Cleaning Medical Equipment Directly Affects Patient Safety and Equipment Longevity
September 16th 2024Hospital-associated infections affect over 1 million US patients annually. Proper medical equipment cleaning and sterilization significantly reduce infection risks, improving patient outcomes and safety.
Top 3 Secrets to Effective Infection Prevention and Control Through Strategic MDRO Surveillance
September 13th 2024Sean Brown’s 2024 Disease Prevention Summit presentation emphasized leveraging technology, prioritizing high-risk patients, and environmental surveillance to enhance infection prevention and control strategies.
